u/sofia_nascimento

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

the formulary is published, read it before you appeal

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

External review was the thing that finally worked. I did not know it existed until a thread on this board.

switching from sema is not a dose conversion, there is no clean equivalence

ask for the batch record before you ask for a discount

Small fix — the figure you quoted is the claimed purity from the certificate, and the independent result was the higher of the two.

Correction: that supplier is in the documented twenty with a source page, not in the wider-market table. Different evidence bases entirely.

Minimum order and lead time — did they quote both up front?

What is the waist doing? That is usually the number still moving during a scale stall.

the appetite effect is blunter than sema, in a good way, most weeks

Which week did the appetite change actually land for you?

Agreed on buying small first. The cost of a test is small next to the cost of committing to a supplier you have not checked.

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.

What did the intake actually ask you?

zepbound and mounjaro are the same compound with different labels

The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 47 is not a fair reading.

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

Pen or vial? The step sizes available differ and it changes this answer.

appeal in writing even when they say a call is enough

a template letter that quotes their own criteria back is the strongest one

the interesting column is spread, not maximum

What is the beyond-use date and what is it based on?

How many separate lots is that across? One lot tested twice is one data point.

Which country and which plan year are we talking about?

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

Cosigning the four-week thing. It is a minimum interval, and treating it as a schedule to keep up with is how people end up miserable at 12.5.

Same view. A record you can read beats a rating you cannot inspect, every time.

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

deadlines run from the letter date, not from when you opened it

Does injection-site soreness follow the day after the shot, or is it spread across the week?

Careful — the deadline runs from the date on the letter. Waiting for a call back can cost you the appeal entirely.

Which week did the appetite change actually land for you?

ask for the batch record before you ask for a discount

Is this a prior authorisation denial or a formulary exclusion?

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

That reads as a recommendation and the source pages deliberately are not. They are a record you use to make your own decision.

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.